October 02, 2025 a 01:00 pm
PODD: Fundamental Ratio Analysis - Insulet Corporation
Insulet Corporation, under the ticker PODD, operates in the healthcare sector, specializing in innovative insulin delivery systems for diabetic patients. With its core product, the Omnipod System, the company has expanded its market reach globally, indicating potential growth while facing competitive risks inherent in medical devices.
Fundamental Rating
The fundamental rating gives an overview of the company's financial health and efficiency. Insulet Corporation has a mixed rating with strengths in certain areas and weaknesses in others.
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 1 | |
| Return On Equity | 4 | |
| Return On Assets | 5 | |
| Debt To Equity | 1 | |
| Price To Earnings | 1 | |
| Price To Book | 1 |
Historical Rating
Analyzing past performance helps gauge the stock's stability and change over time. Below are the scores for the current and previous period ratings:
| Date | Overall Score | DCF | ROE | ROA | Debt/Equity | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-10-01 | 2 | 1 | 4 | 5 | 1 | 1 | 1 |
| Previous | 0 | 1 | 4 | 5 | 1 | 1 | 1 |
Analyst Price Target
Analysts' price targets give insight into potential future stock price movements. The following are consensus price targets:
| High | Low | Median | Consensus |
|---|---|---|---|
| 399 | 322 | 360.5 | 360.5 |
Analyst Sentiment
Analyst recommendations provide additional context for investor interest and sentiment. The distribution among various recommendations is displayed below:
| Recommendation | Count | Distribution |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 29 | |
| Hold | 13 | |
| Sell | 2 | |
| Strong Sell | 0 |
Conclusion
Insulet Corporation demonstrates potential for growth, especially with its innovative solutions in insulin delivery systems. However, the company's current fundamental ratings suggest moderate challenges in financial metrics such as debt management and earning justification. The overall sentiment from analysts leans toward a 'Buy' recommendation, supported by optimistic price targets. Investors may need to weigh the potential for market expansion against financial stability risks. As always, further in-depth analysis and monitoring of market trends are advised.